Clinical application of 18F-FAPI-PETCT in interstitial lung disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600124787

Enrollment

Unknown

Registered

2026-05-18

Start date

2023-02-01

Completion date

Unknown

Last updated

2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibrotic interstitial lung disease

Interventions

Case group:None

Control group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with fibrosing interstitial lung disease 2.Those without severe liver and kidney dysfunction. 3. Obtain informed consent from the patient after approval by the ethics committee. 4.No childbearing requirements in the past 3 months 5.A certain number of healthy volunteers

Exclusion criteria

Exclusion criteria: 1.The patient’s physical condition cannot tolerate the examination. 2.In addition to ILD, patients with other lesions such as space-occupying lesions in the lungs 3.Those with poor compliance 4.Mental illness

Design outcomes

Primary

Measure	Time frame
Maximum Standardized Uptake Valuen;Mean Standardized Uptake Value;Metabolic Active Volume;High-resolution CT quantitative analysis;	—

Secondary

Measure	Time frame
6-Minute Walk Distance;Degree of blood oxygen saturation;Lung function;Total Uptake;The proportion of honeycomb and grid eyes;Fibrosis index;	—

Countries

China

Contacts

Public ContactChen Juan

General Hospital of Ningxia Medical University

13014292231@163.com+86 130 1429 2231

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026